Skip to main content

Tooth Loss

0
Pipeline Programs
5
Companies
10
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Geistlich Pharma
Geistlich PharmaSwitzerland - Root
5 programs
Alveolar ridge preservationN/A1 trial
BioOss Collagen at the time of implant placementN/A1 trial
Collagen Matrix 10808N/A1 trial
allograft + x-link collagen membraneN/A1 trial
xenograftN/A1 trial
Active Trials
NCT06654141Recruiting42Est. Dec 2029
NCT02174198Completed32Est. Aug 2018
NCT02356770Completed20Est. Jul 2013
+2 more trials
ZimVie
ZimVieCO - Westminster
2 programs
T3 Pro dental implant systemN/A1 trial
TSXN/A1 trial
Active Trials
NCT05498662Recruiting60Est. Dec 2026
NCT06571812Recruiting62Est. Jun 2027
Eppendorf
EppendorfGermany - Hamburg
1 program
Dental ImplantsN/A1 trial
Active Trials
NCT04838184Unknown20Est. Mar 2024
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Removable Partial DentureN/A1 trial
Active Trials
NCT06191107Recruiting50Est. Nov 2028
Innovation Pharmaceuticals
1 program
Xenogeneic collagen matrixN/A1 trial
Active Trials
NCT04243460Completed57Est. Mar 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Geistlich PharmaAlveolar ridge preservation
ZimVieTSX
Heidelberg PharmaRemovable Partial Denture
ZimVieT3 Pro dental implant system
Geistlich Pharmaxenograft
EppendorfDental Implants
Geistlich Pharmaallograft + x-link collagen membrane
Geistlich PharmaBioOss Collagen at the time of implant placement
Innovation PharmaceuticalsXenogeneic collagen matrix
Geistlich PharmaCollagen Matrix 10808

Clinical Trials (10)

Total enrollment: 422 patients across 10 trials

NCT06654141Geistlich PharmaAlveolar ridge preservation

Influence of Healing Time on the Outcomes of Alveolar Ridge Preservation in Periodontally Compromised Extraction Sockets

Start: Feb 2025Est. completion: Dec 202942 patients
N/ARecruiting
NCT06571812ZimVieTSX

A Clinical Study of the TSX Dental Implant System (Xpresso)

Start: Apr 2024Est. completion: Jun 202762 patients
N/ARecruiting
NCT06191107Heidelberg PharmaRemovable Partial Denture

Removable Partial Dentures Made of PEEK

Start: Feb 2024Est. completion: Nov 202850 patients
N/ARecruiting
NCT05498662ZimVieT3 Pro dental implant system

An Observational Study of the T3 Pro Dental Implant System

Start: Sep 2022Est. completion: Dec 202660 patients
N/ARecruiting
NCT03659617Geistlich Pharmaxenograft

Healing Dynamics in Human Extraction Sockets Grafted With Bio-Oss Collagen®

Start: Dec 2018Est. completion: May 202539 patients
N/ACompleted
NCT04838184EppendorfDental Implants

Short Implants in Edentulous Mandible

Start: Apr 2015Est. completion: Mar 202420 patients
N/AUnknown
NCT02330523Geistlich Pharmaallograft + x-link collagen membrane

An RCT Comparing Xenograft and Allograft for Ridge Preservation

Start: Apr 2014Est. completion: Dec 201540 patients
N/ACompleted
NCT02174198Geistlich PharmaBioOss Collagen at the time of implant placement

Bone Remodeling After Immediate Implant Placement With and Without Bone Grafting

Start: Jan 2014Est. completion: Aug 201832 patients
N/ACompleted
NCT04243460Innovation PharmaceuticalsXenogeneic collagen matrix

Influence of Soft Tissue Thickness on the Bone Level Around Implants

Start: May 2012Est. completion: Mar 201657 patients
N/ACompleted
NCT02356770Geistlich PharmaCollagen Matrix 10808

A Clinical Study to Investigate Collagen Matrix 10808 for Soft Tissue Volume Augmentation Around Single Implants

Start: Feb 2012Est. completion: Jul 201320 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 422 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.